Suprachoroidal Administration in Subjects With Metastases to the Choroid
← catalyst calendarNCT06643884 · readout in 102 d
Sponsored by Aura Biosciences (industry) · AURA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-16 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Eye Cancer
- Primary Cancer
Interventions
- Drug: AU-011
- Device: SCS Microinjector
- Device: Laser
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.
measured 4 weeks after completion of treatment
Change from baseline in choroidal tumor largest basal diameter (LBD) on fundus photos 4 weeks after completion of treatment.
measured 4 weeks after completion of treatment
Permalink · AURA's whole pipeline · Catalyst calendar · Every registered study · What changed